A Long-term Safety and Tolerability Study of USL261 in Patients With Seizure Clusters
NCT02161185 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 7
Last updated 2019-10-10
Summary
The purpose of this study is to examine the long-term safety and tolerability of USL261 in the treatment of seizure clusters.
Conditions
Interventions
- DRUG
-
USL261
5 mg, intranasal dose for seizure cluster, may repeat as indicated by protocol
Sponsors & Collaborators
-
UCB Biopharma S.P.R.L.
lead INDUSTRY
Principal Investigators
-
TzeChiang Meng, MD · Proximagen, LLC
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 12 Years
- Max Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2014-05-31
- Primary Completion
- 2015-05-31
- Completion
- 2015-05-31
Countries
- United States
Study Locations
More Related Trials
-
Safety and Efficacy of Lacosamide as Additional Therapy in Patients Suffering From Epileptic Tonic-Clonic Seizures
NCT02408549 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Investigate How Effective, Safe and Tolerable the Drug NBI-921352 is When Used With Anti-seizure Medications in Adults With Focal Onset Seizures
NCT05159908 ·Status: COMPLETED ·Phase: PHASE2
-
Extension Study to Evaluate the Safety and Tolerability of NBI-921352 When Used With Anti-seizure Medications in Adults With Focal Onset Seizures
NCT05493293 ·Status: TERMINATED ·Phase: PHASE2
-
Study to Evaluate the Safety and Efficacy of USL261 (Intranasal Midazolam) in Patients With Seizure Clusters
NCT01390220 ·Status: TERMINATED ·Phase: PHASE3
-
Open-Label Study to Assess Lacosamide Safety as Add-on Therapy for Primary Generalized Tonic-Clonic Seizures in Subjects With Epilepsy
NCT01118949 ·Status: COMPLETED ·Phase: PHASE2
-
A Clinical Study to Investigate the Efficacy and Safety of Lacosamide as an Add on Therapy in Children With Epilepsy With Partial-onset Seizures
NCT01964560 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Assess the Long-term Safety of Oral Lacosamide in Subjects With Partial-onset Seizures
NCT00655486 ·Status: COMPLETED ·Phase: PHASE3
-
Trial to Assess Optimized Dosage of Lacosamide as add-on Therapy in Patients With Partial Onset Seizure
NCT01235403 ·Status: COMPLETED ·Phase: PHASE4
-
Open Label Study (Everyone Who Participates Receives Drug) to Further Determine How Safe and Effective Oral Treatment of Seletracetam is in Patients With Refractory Epilepsy.
NCT00175864 ·Status: WITHDRAWN ·Phase: PHASE3
-
Open-Label Extension Study Of Safety And Tolerability Of Pregabalin In Pediatric Patients With Partial-Onset Seizures
NCT00448916 ·Status: COMPLETED ·Phase: PHASE3
-
To Determine Tolerability and Efficacy of Long-term Oral Lacosamide in Patients With Partial Seizures
NCT00552305 ·Status: COMPLETED ·Phase: PHASE2
-
Determine Safety and Efficacy of Long-term Oral Lacosamide in Patients With Partial Seizures
NCT00522275 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Assess the Safety and Tolerability of Intravenous Carbamazepine in Adults With Epilepsy
NCT01128959 ·Status: COMPLETED ·Phase: PHASE3
-
Study Of The Safety And Efficacy Of Lyrica In The Treatment Of Newly Diagnosed Partial Epilepsy
NCT00280059 ·Status: COMPLETED ·Phase: PHASE3
-
Brivaracetam Efficacy and Safety Study in Subjects With Partial Onset Seizures
NCT01261325 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of UCB0942 in Adult Patients With Highly Drug-resistant Focal Epilepsy
NCT02495844 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Assess the Safety and Efficacy of Lacosamide Versus Placebo (a Pill Without Active Medication) in Patients With Idiopathic Generalised Epilepsy Who Are Already Taking Anti-epileptic Medications
NCT02408523 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate the Efficacy and Safety of Seletracetam in Adult Patients With Refractory Partial Onset Seizures
NCT00422110 ·Status: WITHDRAWN ·Phase: PHASE2/PHASE3
-
A 12-Month Study To Evaluate The Safety And Tolerability Of Pregabalin As Add-On Therapy In Pediatric Subjects 1 Month To 16 Years Of Age With Partial Onset Seizures And Pediatric And Adult Subjects 5 To 65 Years Of Age With Primary Generalized Tonic-Clonic Seizures
NCT01463306 ·Status: COMPLETED ·Phase: PHASE3
-
Safety, Tolerability, and Pharmacokinetic Study of Pregabalin in Pediatric Patients With Partial Onset Seizures
NCT00437281 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Study With Seletracetam (Ucb 44212) in Adult Subjects (18 to 65 Years) With Partial Onset Seizures
NCT00152451 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Investigate the Safety and Efficacy of Lacosamide Added to the Patients Current Therapy in Patients Aged 1 Month to Less Than 18 Years Old With Epilepsy Syndromes Associated With Generalized Seizures.
NCT01969851 ·Status: COMPLETED ·Phase: PHASE2
-
Sabril for Complex Partial Seizures in Adult Tolerability Study (TS) Patients
NCT01266291 ·Status: TERMINATED ·Phase: PHASE4
-
Evaluate the Efficacy of BGG492 as Adjunctive Treatment in Patients With Refractory Partial Onset Seizures
NCT01167335 ·Status: WITHDRAWN ·Phase: PHASE2
-
Efficacy and Safety of Lacosamide as Adjunctive Therapy in Subjects ≥1 Month to <4 Years With Partial-onset Seizures
NCT02477839 ·Status: COMPLETED ·Phase: PHASE3